These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33280267)

  • 1. Pluripotent stem cell-based screening identifies CUDC-907 as an effective compound for restoring the in vitro phenotype of Nakajo-Nishimura syndrome.
    Kase N; Terashima M; Ohta A; Niwa A; Honda-Ozaki F; Kawasaki Y; Nakahata T; Kanazawa N; Saito MK
    Stem Cells Transl Med; 2021 Mar; 10(3):455-464. PubMed ID: 33280267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pluripotent Stem Cell Model of Nakajo-Nishimura Syndrome Untangles Proinflammatory Pathways Mediated by Oxidative Stress.
    Honda-Ozaki F; Terashima M; Niwa A; Saiki N; Kawasaki Y; Ito H; Hotta A; Nagahashi A; Igura K; Asaka I; Li HL; Yanagimachi M; Furukawa F; Kanazawa N; Nakahata T; Saito MK
    Stem Cell Reports; 2018 Jun; 10(6):1835-1850. PubMed ID: 29731430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Chinese case of Nakajo-Nishimura syndrome with novel compound heterozygous mutations of the PSMB8 gene.
    Jia T; Zheng Y; Feng C; Yang T; Geng S
    BMC Med Genet; 2020 Jun; 21(1):126. PubMed ID: 32513120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced pluripotent stem cells representing Nakajo-Nishimura syndrome.
    Kanazawa N; Honda-Ozaki F; Saito MK
    Inflamm Regen; 2019; 39():11. PubMed ID: 31143302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new infant case of Nakajo-Nishimura syndrome with a genetic mutation in the immunoproteasome subunit: an overlapping entity with JMP and CANDLE syndrome related to PSMB8 mutations.
    Kunimoto K; Kimura A; Uede K; Okuda M; Aoyagi N; Furukawa F; Kanazawa N
    Dermatology; 2013; 227(1):26-30. PubMed ID: 23942189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction to: Pluripotent Stem Cell-Based Screening Identifies CUDC-907 as an Effective Compound for Restoring the In Vitro Phenotype of Nakajo-Nishimura Syndrome.
    Stem Cells Transl Med; 2023 Mar; 12(2):123. PubMed ID: 36565066
    [No Abstract]   [Full Text] [Related]  

  • 7. Nakajo-Nishimura syndrome and related proteasome-associated autoinflammatory syndromes.
    Ohmura K
    J Inflamm Res; 2019; 12():259-265. PubMed ID: 31576159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nakajo-Nishimura syndrome: an autoinflammatory disorder showing pernio-like rashes and progressive partial lipodystrophy.
    Kanazawa N
    Allergol Int; 2012 Jun; 61(2):197-206. PubMed ID: 22441638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myositis with sarcoplasmic inclusions in Nakajo-Nishimura syndrome: a genetic inflammatory myopathy.
    Ayaki T; Murata K; Kanazawa N; Uruha A; Ohmura K; Sugie K; Kasagi S; Li F; Mori M; Nakajima R; Sasai T; Nishino I; Ueno S; Urushitani M; Furukawa F; Ito H; Takahashi R
    Neuropathol Appl Neurobiol; 2020 Oct; 46(6):579-587. PubMed ID: 32144790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effect of methotrexate on a child case of Nakajo-Nishimura syndrome.
    Kunimoto K; Honda-Ozaki F; Saito MK; Furukawa F; Kanazawa N
    J Dermatol; 2019 Oct; 46(10):e365-e367. PubMed ID: 31058345
    [No Abstract]   [Full Text] [Related]  

  • 11. Nakajo-Nishimura Syndrome: The First African Case.
    Ghodbane NE; Mecibah A; Merzougui Z; Zerguine H; Akakba Z; Slimani S
    Mediterr J Rheumatol; 2023 Jun; 34(2):262-265. PubMed ID: 37654638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nakajo-Nishimura syndrome].
    Kanazawa N; Arima K; Ida H; Yoshiura K; Furukawa F
    Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(5):388-400. PubMed ID: 22041427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chinese case of Nakajo-Nishimura syndrome with a novel mutation of the PSMB8 gene.
    Shi X; Xiang X; Wang Z; Ma L; Xu Z
    J Dermatol; 2019 May; 46(5):e160-e161. PubMed ID: 30387862
    [No Abstract]   [Full Text] [Related]  

  • 14. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
    Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y
    Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.
    Zhang D; Damoiseaux R; Babayan L; Rivera-Meza EK; Yang Y; Bergsneider M; Wang MB; Yong WH; Kelly K; Heaney AP
    J Clin Endocrinol Metab; 2021 Jan; 106(1):e232-e246. PubMed ID: 33000123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
    Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
    Guo H; Zeng D; Zhang H; Bell T; Yao J; Liu Y; Huang S; Li CJ; Lorence E; Zhou S; Gong T; Jiang C; Ahmed M; Yao Y; Nomie KJ; Zhang L; Wang M
    Oncogene; 2019 Mar; 38(11):1802-1814. PubMed ID: 30361685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia.
    Ishikawa C; Mori N
    Eur J Haematol; 2020 Dec; 105(6):763-772. PubMed ID: 32780889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
    Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
    J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.